Form 4: LENZ Therapeutics Director Kimberlee Drapkin Granted 13,500 Stock Options

LENZ Therapeutics, Inc. Director Kimberlee C. Drapkin was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026.

Summary

• Kimberlee C. Drapkin, a Director of LENZ Therapeutics, Inc. (LENZ), was granted 13,500 stock options.
• The options have an exercise price of $30 per share.
• The transaction date for this grant was June 11, 2025.
• The options are subject to a vesting schedule, with 100% of the shares vesting on June 11, 2026.
• Vesting is contingent upon Ms. Drapkin continuing to serve as an Outside Director as defined by the Issuer's Outside Director Compensation Policy.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Ms. Drapkin beneficially owns 13,500 derivative securities (stock options).
• A Power of Attorney was executed on June 11, 2025, authorizing specific individuals to prepare and file SEC reports on behalf of Ms. Drapkin.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event for the director as compensation and generally neutral to slightly positive for the company as it aligns interests. There are no negative financial or operational disclosures.

Positives

• The grant of 13,500 stock options provides a significant incentive for Director Kimberlee C. Drapkin to contribute to the company's long-term success.
• The options align the director's interests with those of shareholders, as the value of the options increases with the company's stock price.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if the options are exercised.

Risks

• The vesting of the 13,500 stock options for Director Kimberlee C. Drapkin is contingent upon her continued service as an Outside Director until June 11, 2026. If her directorship ceases before this date, the options may not vest.

Future Outlook

The document indicates that 100% of the granted stock options will vest on June 11, 2026, provided the reporting person continues to serve as an Outside Director. The options have a long-term expiration date of June 10, 2035, allowing for future potential exercise.

Industry Context

This Form 4 filing reflects a standard practice of compensating non-employee directors with equity grants, which is common across various industries, including biotechnology and pharmaceuticals, to align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to an outside director is a common compensation practice in publicly traded companies, particularly in the biotechnology sector like LENZ Therapeutics, Inc.
• The vesting schedule (one year cliff vesting) is a typical structure for director equity grants, designed to incentivize continued service.
• The exercise price of $30 is likely the fair market value of the stock on the grant date, which is standard for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of 13,500 stock options to Kimberlee C. Drapkin, a Director of LENZ Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from increased alignment of director's interests with long-term shareholder value.
• Director (Kimberlee C. Drapkin): Receives significant equity compensation, incentivizing continued performance and commitment to the company.

Next Steps

• The 13,500 stock options are scheduled to vest on June 11, 2026, subject to the director's continued service.
• The options can be exercised at any time after vesting until their expiration on June 10, 2035.

Key Dates

Keywords

LENZ Therapeutics, LENZ, Stock Option, Form 4, SEC Filing, Director Compensation, Equity Grant, Kimberlee Drapkin, Derivative Securities, Vesting